HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Supplement Industry Rides Growth Amid Changes After Year Of Covid-19 Pandemic

Executive Summary

“Many of those initial fears have abated as companies have learned more about transmission and how to protect staff,” says Tara Couch, EAS Consulting. But industry is changed and manufacturers are thinking more intently about supply chains and manufacturing processes.

You may also be interested in...

‘Go Try To Find Some Zinc Gluconate’: The Dietary Supplement Supply Chain Entering 2022

Ingredients for immune health supplements are in short supply as high demand persists in the US. CEOs Mark LeDoux of Natural Alternatives International and Jim Emme of NOW Health Group, both on the Natural Products Association’s board of directors, discuss ongoing supply issues and best practices to avoid problems.

AHPA Asks US To Lift Tariffs On Imports From China Weighing Down Supplement Firms

AHPA asks USTR Katherine Tai to eliminate punitive tariffs Trump administration imposed on certain Chinese ingredients used by supplement companies. With costs up, many US supplement firms are operating on net margins of less than 10%.

Bloom In US Demand For Immunity Supplements Prompts Abbott, Star Nutra And PRTCL Launches

Abbott expands Pedialyte children’s line with adult products including Immune Support beverage in response to consumer demands for nutritional supplements to support immune health; Star Nutra introduces gummy immunity supplements; and PRTCL has a women’s immune-boost product.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts